Benjamin Edwards Inc. Has $572,000 Stake in Twist Bioscience Co. (NASDAQ:TWST)

Benjamin Edwards Inc. boosted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 10,120.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,673 shares of the company's stock after purchasing an additional 12,549 shares during the quarter. Benjamin Edwards Inc.'s holdings in Twist Bioscience were worth $572,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of TWST. Thrivent Financial for Lutherans acquired a new position in Twist Bioscience in the third quarter worth about $43,992,000. Point72 Asset Management L.P. grew its stake in shares of Twist Bioscience by 1,021.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company's stock valued at $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC lifted its position in shares of Twist Bioscience by 720.7% during the 2nd quarter. Fred Alger Management LLC now owns 654,877 shares of the company's stock worth $32,272,000 after buying an additional 575,080 shares during the period. Victory Capital Management Inc. lifted its position in shares of Twist Bioscience by 4,133.1% during the 2nd quarter. Victory Capital Management Inc. now owns 308,171 shares of the company's stock worth $15,187,000 after buying an additional 300,891 shares during the period. Finally, Farallon Capital Management LLC bought a new stake in Twist Bioscience in the second quarter valued at $9,462,000.

Analyst Upgrades and Downgrades

TWST has been the subject of a number of analyst reports. Robert W. Baird lifted their price objective on Twist Bioscience from $46.00 to $48.00 and gave the company an "outperform" rating in a report on Tuesday, November 19th. Evercore ISI lifted their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. Leerink Partners lifted their target price on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research note on Thursday, October 17th. Finally, TD Cowen restated a "buy" rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Twist Bioscience presently has a consensus rating of "Moderate Buy" and a consensus price target of $51.00.

Twist Bioscience Stock Up 3.9 %

TWST stock traded up $1.96 during trading on Friday, hitting $52.70. The company had a trading volume of 512,209 shares, compared to its average volume of 941,345. The firm has a 50-day moving average price of $44.36 and a 200-day moving average price of $46.41. Twist Bioscience Co. has a 12 month low of $24.81 and a 12 month high of $60.90. The stock has a market cap of $3.13 billion, a price-to-earnings ratio of -14.64 and a beta of 1.82.

Insider Activity

In related news, CEO Emily M. Leproust sold 1,730 shares of Twist Bioscience stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the sale, the chief executive officer now directly owns 495,523 shares of the company's stock, valued at $23,259,849.62. The trade was a 0.35 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Chess sold 3,600 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $47.26, for a total value of $170,136.00. Following the completion of the transaction, the director now directly owns 21,641 shares in the company, valued at $1,022,753.66. The trade was a 14.26 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 98,118 shares of company stock valued at $4,391,151. Company insiders own 3.92% of the company's stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.